Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Century Therapeutics submits IPO filing
The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.
Centessa captures $330m in IPO
Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.
Effector exercises reverse merger
UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.
Oatly floats on Nasdaq
The Lund research-based oat milk brand has floated in a $1.43bn IPO on the Nasdaq Global Select Market after pricing shares at $17.
Norsk Titanium nets $38m amid listing
SUNY Polytechnic University-backed Norsk Titanium has begun trading on Euronext Growth Oslo.
Vera unveils IPO pricing
Yale's immunological disease treatment developer floated its shares below its initial price range in an IPO in the US.
Cizzle checks out reverse merger
York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.
Ginkgo Bioworks gears up for $17.5bn merger
MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.

Other News

Gyroscope Therapeutics gives up $149m IPO
Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.
Jasper Therapeutics jumps at reverse merger opportunity
The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.
Talaris debuts on Nasdaq
Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.
Werewolf Therapeutics hunts $120m in IPO
The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.
Vaccitech injects shares into public market
Vaccitech, which developed the technology underlying Oxford’s covid vaccine, has priced its shares and will raise more than $110m in its IPO.
Vera Therapeutics vies for public markets spot
Yale’s immunological and inflammatory disease therapy developer has filed for an offering with an $86.3m placeholder target.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg